FRIENDSWOOD, Texas, May 10, 2024--Castle awarded the "Best Overall Mental Health Solution" in 8th annual MedTech Breakthrough Awards program for IDgenetix® pharmacogenomic (PGx) test
FRIENDSWOOD, Texas, May 08, 2024--Castle announced data supporting the utility of the PRAME biomarker as a risk refinement tool when considered in the context of a DecisionDx-UM result
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.